VIR - NASDAQ

Vir Biotechnology, Inc.

VIR·NASDAQ

$8.77

+0.34%

HealthcareBiotechnology

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.48B

EPS-3.1600

P/E Ratio-2.78

Earnings Date08/05/2026

1.00B

Assets

-28%

3Y-64.0%

5Y+9.0%

10Y+299.0%

237.55M

Total Liabilities

-4%

3Y-67.0%

5Y+18.0%

10Y-26.0%

765.28M

Total Equity

-33%

3Y-63.0%

5Y+7.0%

10Y-1210.0%

Vir Biotechnology, Inc. Funding & Solvency Profile

VIR · NASDAQ

Current Assets

Cash & Cash Equivalents234.11M

Net Receivables3.60M

Inventory0.00

Other Current Assets47.62M

Total Current Assets514 M

Non-Current Assets

Property, Plant & Equipment117.72M

Goodwill & Intangible Assets24.79M

Long-Term Investments314.57M

Other Non-Current Assets31.66M

Total Non-Current Assets464 M

Total Assets

1.00B

Financial Health Analysis

Current Ratio

5.54x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.31x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

421 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

51% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Vir Biotechnology, Inc. Balance Sheet

VIR • NASDAQ

Vir Biotechnology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	234.1M	222.9M	241.6M	848.6M	347.8M	436.6M	109.3M	47.6M	187.9M
Short-Term Investments	228.8M	682.4M	1.3B	1.6B	360.3M	300.3M	274.1M	50.8M	0.0
Cash & Short-Term Investments	462.9M	905.3M	1.5B	2.4B	708.1M	736.9M	383.4M	98.4M	187.9M
Net Receivables	3.6M	0.0	0.0	0.0	773.1M	0.0	0.0	0.0	0.0
Other Receivables	3.6M	0.0	0.0	0.0	773.1M	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	57.8M	73M	27.5M	13.4M	8.6M	4.4M
Other Current Assets	47.6M	137.1M	65.8M	59.2M	8.6M	8M	6.2M	10.8M	0.0
Total Current Assets	514.1M	1B	1.6B	2.5B	1.6B	772.4M	403M	117.8M	192.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	117.7M	122.9M	167.2M	188.2M	130.1M	79.9M	16.3M	12.3M	5.1M
Goodwill	16.9M	16.9M	16.9M	16.9M	16.9M	16.9M	16.9M	16.9M	16.9M
Intangible Assets	7.9M	8.1M	22.6M	32.8M	33.3M	33.8M	35.7M	36.9M	35.9M
Goodwill & Intangible Assets	24.8M	25M	39.5M	49.7M	50.2M	50.8M	52.6M	53.9M	52.8M
Long-Term Investments	314.6M	190M	105.3M	23.9M	201.4M	0.0	24.3M	7.7M	1M
Tax Assets	0.0	0.0	0.0	249.7M	0.0	0.0	0.0	-7.7M	-1M
Other Non-Current Assets	31.7M	18.4M	18.9M	-228.5M	9.8M	15.7M	15.8M	7.7M	1.3M
Total Non-Current Assets	488.7M	356.3M	330.8M	283M	391.4M	146.4M	109M	73.8M	59.2M
Other Assets	0.0	22K	0.0	0.0	0.0	0.0	33K	0.0	0.0
Total Assets	1B	1.4B	1.9B	2.8B	2B	918.8M	512.1M	191.6M	251.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.8M	16.7M	6.3M	21.7M	109.6M	8.5M	6M	6.5M	4.9M
Accounts Payable	9.8M	5.1M	6.3M	6.4M	6.5M	5.1M	5.9M	6.5M	4.9M
Other Payables	0.0	11.6M	0.0	15.2M	103M	3.5M	94K	0.0	0.0
Accrued Expenses	0.0	66.5M	82M	462.1M	129.5M	69.8M	24.7M	2.7M	7.5M
Short Term Debt	8.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	7.8M	12.9M	4.1M	3.9M	3.6M	237K	0.0	0.0
Tax Payables	0.0	0.0	149K	15.2M	6.2M	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	12.6M	64.9M	15.5M	98.2M	6.5M	6.2M	8.8M	0.0
Other Current Liabilities	74.2M	16.1M	9.4M	7.7M	0.0	10.6M	22.1M	22M	0.0
Total Current Liabilities	92.8M	119.7M	175.4M	511M	341.2M	99.1M	59.2M	39.9M	12.4M
NON-CURRENT LIABILITIES
Long Term Debt	89.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	1.5M	53.2M	3.8M	3.8M	12.7M	6.6M	888K
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	3.3M	18.4M	3.3M	3.3M	3.3M	3.3M
Other Non-Current Liabilities	-33.4M	38.6M	40.2M	32.8M	25.4M	29.2M	12.9M	10.8M	10.4M
Total Non-Current Liabilities	144.7M	128.8M	153.4M	213.1M	181.2M	102.8M	28.9M	330.9M	308M
Capital Lease Obligations	89.1M	97.9M	124.5M	128M	137.5M	70.2M	237K	0.0	0.0
Total Liabilities	237.5M	248.4M	328.8M	724.1M	522.4M	201.9M	88.1M	370.8M	320.5M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-14.7M	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	309.1M	292.5M
Common Stock	14K	14K	13K	13K	13K	13K	11K	1K	1K
Additional Paid-In Capital	2B	1.9B	1.8B	1.7B	1.6B	1.4B	793.1M	14.7M	9M
Retained Earnings	-1.2B	-759.8M	-237.8M	377.2M	-138.6M	-667.2M	-368.5M	-193.8M	-78M
Accumulated Other Comprehensive Income/Loss	-2.1M	-1.7M	-815K	-9.1M	-1.1M	-1.3M	-601K	-14K	-292.5M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-294.5M	292.5M
Total Stockholders' Equity	765.3M	1.2B	1.6B	2.1B	1.4B	716.9M	423.9M	-179.2M	-68.9M
Total Equity	765.3M	1.2B	1.6B	2.1B	1.4B	716.9M	423.9M	-179.2M	-68.9M
SUMMARY
Total Liabilities & Equity	1B	1.4B	1.9B	2.8B	2B	918.8M	512.1M	191.6M	251.6M
Total Investments	543.3M	872.4M	1.4B	1.6B	561.7M	300.3M	298.4M	58.5M	1M
Total Debt	186.9M	97.9M	124.5M	128M	137.5M	70.2M	237K	10.1M	0.0
Net Debt	-47.2M	-125.1M	-117M	-720.7M	-210.3M	-366.4M	-109.1M	-37.5M	-187.9M
Shares Outstanding	139,113,702	139,113,702	139,113,702	139,113,702	139,113,702	139,113,702	139,113,702	139,113,702	139,113,702

SEC Filings

VIR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 28, 2026	May 25, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 16, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 10, 2026	April 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 23, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 136 filings

Related Guides

Blog Categories

Continue your VIR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.